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Abstract
Introduction. The aim of this study was to assess adherence to treatment with use of the new scale in a population of 
patients with coronary artery disease (CAD) after myocardial infarction (MI) with respect to some socio-demographic 
and clinical factors.
Material and methods. The study was conducted in a population of 100 consecutive patients (40 women, 60 men) aged 
from 30 to 88 years (mean 63.4), six months after hospitalization for MI.
Results. The results of the assessment with the Adherence in Chronic Diseases Scale (ACDS) comprise between 6 and 
28 points; median 24 points (21–28). Twenty-four patients had high score (> 26 pts.), 53 patients had intermediate 
score (between 21–26 pts.) and 23 — low score (< 21 pts.). For optimal model of multiple regression, the correla-
tion coefficient R was 0.539; and the adjusted coefficient of determination R2 = 0.26, p = 0.000002. Independent 
factors affecting adherence according to the ACDS scale were: subjective assessment of health status (b = 0.48 ± 
± 0.23, p = 0.036), age of the respondents (b = –0.11 ± 0.04, p = 0.004), more than one hospitalization due to CAD 
(b = –1.78 ± 0.87, p = 0.044), and diabetes mellitus (b = –2.02 ± 0.91, p = 0.029).
Conclusions. Subjective assessment of health status, age of patients, the number of hospitalizations due to CAD and 
diabetes affect the adherence in the course of long-term treatment after myocardial infarction.
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Introduction
Implementation of treatment plan is a prerequisite for 
the effectiveness of treatment in patients with chronic 
diseases. Therapeutic effect expected based on large 
clinical trials can be achieved provided that the patient 
regularly takes medications [1]. According to the evaluation 
carried out by the World Health Organization in developed 
countries, only about 50% of chronically ill patients follow 
the recommendations of his or her healthcare provider [2]. 
Such a large scale of poor adherence by patients not only 
adversely influences their health, but also implies serious 
social and economic consequences [3].
A paper published by the Canadian researchers evalu-
ated the implementation of the treatment plan in terms 
of the use of statins [4]. Out of 112,092 patients without 
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known cardiovascular disease in whom statin therapy had 
been initiated, 55% did not take prescribed medications. 
The incidence of cerebrovascular events was significantly 
lower (relative risk [RR]: 0.74; 95% confidence interval [CI] 
0.65–0.84) in those who adhere to physician’s recommen-
dations compared with the other patients [4]. Similarly, 
results of the PREMIER (Prospective Registry Evaluating 
Myocardial Infarction: Event and Recovery) trial indicated 
that poor implementation of the treatment plan is the most 
important reason for the limited effectiveness of treatment 
[5]. In a population of patients after myocardial infarction 
(MI) assessed at one month after discharge from the hospi-
tal with the recommendation of aspirin, a beta-adrenolytic 
and a statin, 12% of patients discontinued taking all three 
drugs, 4% — two drugs, and 18% — one drug. One-year 
survival rate of patients who completely stopped taking 
the drugs was significantly lower compared with those who 
continued their therapy (88.5% vs. 97.7%) [5].
Analysis of the factors determining the effectiveness 
of antiplatelet therapy in patients after MI showed that 
the incidence of pseudo-resistance to therapy due to not 
taking drugs increases with the passage of time [6]. This 
is due to many factors, including the complexity of the 
therapy, the frequency of dosing, economic factors, the 
side effects of therapy, and the patient’s conviction that 
the treatment is necessary, especially in the absence of 
clinical symptoms [1].
The preferred term for implementation of treatment 
plan is “adherence”. This term denotes the joint (doctor 
and patient) development of treatment plans and their 
implementation [1, 3]. Good cooperation of medical per-
sonnel with patients is a fundamental factor for treatment 
effectiveness in patients with chronic diseases, such as 
coronary artery disease (CAD), diabetes and hypertension 
[7]. In everyday practice, the two parties do not always 
manage to have good contact, which is a prerequisite for 
cooperation [8].
For the implementation of the treatment plan, it is 
important to know the true adherence of the patient, un-
derstand the causes of low adherence and take actions to 
improve adherence [9]. There are some direct and indirect 
methods of assessing adherence; however, it is impossible 
to indicate the best one [3, 10–12]. Direct methods are 
observation of the therapy process, determining the con-
centration of the drug or its metabolites in body fluids and 
measuring biological markers. Indirect methods include: 
surveys of patients using developed scales, analysis of 
pharmacy records, the use of electronic forms of drug-tak-
ing monitoring (e.g., containers recording how often and 
when it was accessed), observation of the changes in pa-
tient’s clinical situation, and assessment of the dynamics 
of the disease process [1, 3].
The simplest and most common way to assess adher-
ence is obtaining information directly from the patient. 
However, it has been shown that the data obtained in this 
way have limited credibility [9]. Objectification of patient-re-
ported information on treatment plan implementation is 
usually difficult and costly. The use of specially developed 
scales to assess the risk of low adherence allows extensive 
screening.
The aim of this study was to assess adherence us-
ing the new scale in a population of patients with CAD 
6 months after MI, in relation to sociodemographic and 
clinical parameters.
Material and methods
The study was conducted in a population of 100 conse-
cutive patients (40 women, 60 men) with a mean age of 
63.4 (30–88) years who were assessed six months after 
hospitalization for MI. The study was conducted between 
May 2015 and January 2016. The results of the assess-
ment of adherence were related to sociodemographic 
data, selected clinical parameters and subjective health 
assessment (Table 1). Respondents rated their health on 
a scale of 1 to 10, where 1 meant very bad health and 
10 — very good health.
Statistical methods
For comparison of the results obtained with the Chronic 
Diseases Adherence Scale (ACDS) nonparametric tests 
were used. Quantitative variables are expressed as me-
dians and quartile ranges. Median values of two data 
series were compared using the Mann-Whitney test. For 
comparison of more series of data, Kruskal-Wallis test and 
multiple comparisons were employed. In order to assess 
the relationship between two quantitative variables, Spear-
man’s rank correlation was used. Multivariate analysis was 
performed using multiple regression. In order to select the 
best regression models, backward stepwise regression was 
performed. Values of p < 0.05 were considered statistically 
significant. The p-values ≥ 0.05 to < 0.10 were regarded 
as a trend towards statistical significance. The calculations 
were performed with the software package Statistica 12.0, 
in Polish (StatSoft, Tulsa, United States).
Assessment of adherence
The ACDS (Table 2) is a new tool to assess the implemen-
tation of the treatment plan. The scale for chronic diseases 
includes 7 questions with sets of 5 suggested answers to 
each question. The questions consider the behavior directly 
determining adherence (Questions 1–5), as well as the 
situations and views that may indirectly affect adherence 
(Questions 6 and 7). The ACDS is designed for surveying 
adults treated for chronic diseases. This tool not only has 
to reflect the actual implementation of the treatment plan 
in terms of pharmacotherapy, but also indicate the mech-
anisms that determine adherence of patients. The results 
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can be helpful in undertaking activities aimed at improving 
the regularity of medication in clinical practice.
The scale was validated previously in the group of 
413 patients with coronary heart disease [13]. The ACDS 
is available free of charge on the website of the Depart-
ment of Health Promotion CM UMK (http://www.cm.umk.
pl/wydzialy/wydzial-nauk-o-zdrowiu/jednostki-wydzialowe/ 
/katedra-i-zaklad-promocji-zdrowia. html).
Results
The results of the assessment of adherence according to 
the ACDS in the study population of 100 people six months 
after MI were between 6 and 28 points; the median score 
was 24 points (21–28 pts.). Twenty-four patients had high 
Table 1. Characteristics of the study population
Parameter Category/value Number of patients
Gender Women 
Men
40 
60
Age < 65 years 
≥ 65 years
56 
44
Education Primary 
Vocational 
Secondary 
Higher
12 
28 
41 
19
Employment 
status
Employed 
Unemployed 
Retiree 
Pensioner
44 
2 
45 
9
Marital status Unmarried 
Married 
Widowed
8 
73 
19
Hospitalization for 
coronary artery 
disease
1 
> 1
61 
39
Myocardial in-
farction
1 
> 1
78 
22
Smoking (cur-
rently)
Yes 
No
32 
68
Diabetes Yes 
No
30 
70
Subjective as-
sessment of he-
alth status
1 
2 
3 
4 
5 
6 
7 
8 
9 
10
0 
0 
3 
8 
16 
10 
16 
23 
11 
10
score (> 26 pts.), 53 patients had intermediate score 
(21–26 pts.) and 23 patients had low score (< 21 pts.).
Univariate analysis
There were no significant differences between women 
(23 pts. [19.5–26.5]) and men (24 pts. [22–26]). We found 
that adherence was decreasing with age (Spearman R = 
= –0.39, p = 0.00007) (Figure 1).
In the group of patients younger than 65 years of age, 
the ACDS score was 24.5 pts. (22.5–27 pts.) and in patients 
aged 65 years and older it was 22 points (19.5–25 pts.), 
p = 0.003. In the surveyed population, the level of education 
was not the differentiating factor in terms of adherence. 
Due to the large disproportions in the number of patients 
in subgroups specified based on employment status, when 
analyzing the results we compared the group of employed 
patients (24 pts. [22.5–27]) with professionally inactive 
patients (combined groups of unemployed, pensioners and 
retirees — 22 points [20–26]), p = 0.043. Similarly, due to 
large disproportions in the number of patients in the sub-
groups divided according to marital status, we compared 
married patients (24 pts. [22–27]) with the combined group 
of “unmarried” and “widowed” (21 pts. [19–26]), p = 0.06. 
In the group of patients hospitalized once due to CAD, ad-
herence was higher than in those who were hospitalized 
more than once: 24 points (21–27 pts.) and 23 points 
(19–26 pts.), respectively; p = 0.024. Similar results were 
obtained when compared people with a history of one 
MI to those who have had more than one MI: 24 points 
(21–27 pts.) and 22 points (18–24 pts.), respectively; 
p = 0.015. There was no effect of smoking on adherence. 
Diabetic patients were characterized by the lower ACDS 
scores compared to diabetes-free patients: 21 points (19– 
–24 pts.) and 24 points (22–27 pts.), respectively; p = 0.005.
The higher subjective evaluation of health status, the 
higher was ACDA score, p = 0.023 (Figure 2). The corre-
lation between these variations was weak but significant: 
R = 0.37, p = 0.00012 (Figure 3).
Multivariate analysis
For optimal model of multiple regression, correlation coeffi-
cient R is 0.539, and the adjusted coefficient of determina-
tion R2 = 0.26; p = 0.000002. Independent factors affecting 
adherence assessed by the ACDS are: subjective assess-
ment of health status (b = 0.48 ± 0.23, p = 0.036), age of 
the respondents (b = –0.11 ± 0.04, p = 0.004), more than 
one hospitalization due to CAD (b = –1.78 ± 0.87, p = 0.044) 
and diabetes mellitus (b = –2.02 ± 0.91, p = 0.029).
Discussion
In the population of our study, high adherence was found 
in 24% and low in 23% of patients. It should be noted, 
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Table 2. The Adherence in Chronic Diseases Scale (ACDS) (source [2])*
Below is a set of 7 questions with answers. Please rate, which response best reflects your behavior, your situation and your opinions. 
Please provide honest answers by checking the appropriate one with X.
1. Do you always remember to take all your medications according to your doctor’s instructions?
A. Always B. Almost always C. Sometimes D. Hardly ever E. Never
2. Do you happen to change the dosing of your medications without prior consultation with your doctor?
A. Never B. Only occasionally C. Sometimes D. Frequently E. I do not adhere to my doctor’s 
recommendations at all
3. Do you adjust the dosing of your medications according to how you feel?
A. No, I strictly follow the prescribed dosing, no matter how I feel
B. Yes, I reduce the dosage of some medications when I feel good
C. Yes, I skip doses of some medications when I feel good
D. Yes, I temporarily discontinue some medications when I feel good
E. Yes, I discontinue all medications when I feel good
4. On the appearance of medication-related side effects (e.g. stomach pain, liver pain, rash, lack of appetite, oedema):
A. I seek medical attention instantly
B. I reduce the dosage of the medication and attempt to expedite the elective appointment with my doctor
C. I discontinue the medication and attempt to expedite the elective appointment with my doctor
D. I discontinue the medication and wait for the next elective appointment with my doctor
E. I discontinue all my medications and wait for the next elective appointment with my doctor
5. Do you find all your medications necessary for your health?
A. Yes, I do
B. I find most of my medications to be beneficial for my health
C. I find only some of my medications to be beneficial for my health
D. I find some of my medications to be beneficial for my health, while the others to be harmful for me
E. I find the majority of my long-term medications to be harmful for me
6. Does your doctor inquire about medication-related problems that you might possibly experience?
A. Yes, on every 
appointment
B. Yes, he/she usually 
does
C. Yes, but only 
sometimes
D. Yes, but only 
occasionally
E. No, never
7. Do you tell truth when asked by your doctor about medication-related problems?
A. Yes, always
B. Almost always
C. I try to be honest, but sometimes it is hard to admit to non-compliance with doctor’s recommendations
D. Sometimes yes, another time no
E. No, I don’t. I find it my own private business
Evaluation of the results
Results are within the range of 0–28 points
Score Total score < 21 points Low adherence
A — 4
B — 3
C — 2 Total score 21–26 points Medium adherence
D — 1
E — 0 Total score > 26 points High adherence
*The Adherence in Chronic Diseasese Scale is available on the website of the Faculty of Health Science of the Nicolaus Copernicus University, Collegium Medicum  
(http://www.cm.umk.pl/wydzialy/wydzial-nauk-o-zdrowiu/jednostki-wydzialowe/katedra-i-zaklad-promocji-zdrowia.html)
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however, that patients’ adherence differs considerably 
between different groups of patients. Differences are also 
observed in relation to specific drugs [14]. The PURE study 
showed that adherence to secondary prevention therapy 
was more influenced by general socioeconomic factors at 
the national level than to individual factors, such as age, 
gender, education level, smoking, body mass index (BMI), 
hypertension and diabetes [15].
As reported by Ho et al. [5], based on the data from 
the PREMIER (Prospective Registry Evaluating Myocar-
dial Infarction: Event and Recovery) study in a group of 
1,521 patients after myocardial infarction discharged from 
the hospital with the recommendation of combination 
therapy with 3 drugs (aspirin, a beta-blocker and a statin), 
one month after discharge more than 1/3 of the patients 
failed to follow, to a greater or lesser extent, the treatment 
Figure 1. Relationship between the Adherence in Chronic Diseases Scale (ACDS) score and age
30
28
26
24
22
20
18
16
14
12
10
8
6
4
20 30 40 50 60 70 80 90 100
Age [years]
A
C
D
S
 [
p
o
in
ts
]
ACDS = –0.1626 × age + 33.321
Spearman R = –0.39
p = 0.00007
Figure 2. Results of the Adherence in Chronic Diseases Scale (ACDS) in groups divided by subjective health status assessment (marker — 
median, box edges — upper and lower quartile, whiskers — non-outlier range)
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plan. Multivariate analysis showed that the probability of 
discontinuation of all three drugs was higher among those 
with higher education (hazard ratio 1.76). The impact of 
older age on treatment discontinuation was higher among 
women (hazard ratio 1.77) than among men (hazard ratio 
1.23). Discontinuation of treatment was an independent 
risk factor for death (hazard ratio 3.81) [5]. The lack of cor-
relation between education level and adherence evaluated 
based on the ACDS score might have been related to the 
relatively small sample size in our study.
The age of patients is one of the most frequently 
reported factors affecting adherence [16–21]. Also our 
study confirmed these observations. Comorbidity burden 
increasing with age is associated with the necessity of 
polypharmacy. Elderly patients often do not understand 
the reasons for the complexity of the treatment and have 
problems with remembering of, adaptation to and compli-
ance with the treatment schedule [22]. This is confirmed 
by the results of PACE (Pennsylvania Pharmaceutical As-
sistance Contract for the Elderly), a retrospective cohort 
study. The analysis of the results of logistic regression 
showed that in elderly patients with hypertension, adher-
ence to the treatment plan was worse in the coexistence 
of asthma or chronic obstructive pulmonary disease (odds 
ratio [OR] = 0.43), depression (OR = 0.5), gastrointestinal 
disorders (OR = 0.59), or musculoskeletal diseases (OR 
= 0.63) compared with hypertensive patients without 
concomitant diseases (OR = 1.0) [23]. At the same time, 
it has been shown that polypragmasy negatively impacts 
the implementation of the treatment plan [17]. In our 
study, the co-existence of diabetes was an independent 
factor reducing adherence. Indirectly, it also corresponds 
to negative correlation between the subjective assess-
ment of the health status and the ACDS score that was 
observed in our patients.
Some researchers have indicated the female gender as 
a risk factor for low adherence [16, 17, 23–25], but this 
was not confirmed by our findings. In contrast to the results 
of other studies [15, 16], we did not observe the impact of 
the level of education on adherence in our patients.
Haynes et al. [26] suggested the following causes of 
nonadherence to physician’s recommendations: adverse 
effects of therapy, insufficient instructions, patients hav-
ing memory problems, poor financial status preventing 
purchasing of medicines, lack of acceptance of the need 
for treatment by the patient, poor relationship between the 
patient and medical staff.
It seems that higher number of hospitalizations due 
to CAD and MI should be related to better understanding 
of the causes of the disease and a greater reflection on 
the need for following the treatment regimen, and con-
sequently to a better adherence. However, the opposite 
tendency was observed in our study. It can be assumed 
that MI was a consequence of a lack of implementation of 
the treatment plan after previous ischemic events. Such 
an interpretation of the results may be questionable, but 
to obtain a definite answer, further prospective studies 
are necessary, since no data on that issue are available in 
the literature. Unexpected results emphasize the practical 
value of the ACDS in identifying populations at particularly 
Figure 3. Relation between the Adherence in Chronic Diseases Scale (ACDS) score and subjective assessment of health status
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high risk of the recurrence of ischemic events. Identifica-
tion of these patients will allow for providing personalized 
educational intervention.
Failure to follow the treatment plan is a relatively 
common problem characterized by population-based 
differences, which is a serious and often underestimated 
factor limiting the effectiveness of treatment. At the same 
time there is no “gold standard” or a universal tool for 
determining the level of adherence. Using a well-designed 
questionnaire gives medical staff the opportunity to identify 
the barriers, gaps in patients’ knowledge and the problems 
in cooperation with patients. The scale is easy to use and 
can be utilized everyday medical practice. Its strength is 
the ability to assess a wide range of the attitudes and 
behaviors of the patient including the essential elements 
of the treatment process.
Conclusions
Subjective assessment of health status, age of patients, 
the number of hospitalizations due to CAD and the co-oc-
currence of diabetes are independent factors affecting 
adherence to chronic therapy after MI. The Adherence in 
Chronic Diseases Scale can be successfully used as a tool 
to support medical staff in identifying patients requiring 
personalized educational activities.
Streszczenie
Wstęp. Celem pracy była ocena adherence z zastosowaniem nowej skali w populacji osób z chorobą wieńcową (CAD) 
po zawale serca (MI) w odniesieniu do parametrów socjodemograficznych i klinicznych.
Materiał i metody. Badanie przeprowadzono w populacji 100 kolejnych osób (40 kobiet, 60 mężczyzn) w wieku 30–88 lat, 
średnio 63,4 roku, pół roku po hospitalizacji z powodu MI.
Wyniki. Wyniki oceny w Adherence in Chronic Diseases Scale (ACDS) zawierały się między 6 a 28 punktów; mediana wy-
nosiła 24 punkty (21–28). Wynik wysoki (> 26 pkt.) osiągnęły 24 osoby, 53 badanych uzyskało wynik średni (między 21 
a 26 pkt.), a 23 — niski wynik (< 21 pkt.). Dla optymalnego modelu regresji wielorakiej współczynnik korelacji R wynosił 
0,539, a skorygowany współczynnik determinacji R2 — 0,26 (p = 0,000002). Niezależnymi czynnikami wpływającymi 
na adherence ocenianymi w ACDS były: subiektywna ocena stanu zdrowia (b = 0,48 ± 0,23; p = 0,036), wiek badanych 
(b = –0,11 ± 0,04; p = 0,004), więcej niż jeden pobyt w szpitalu z powodu CAD (b = –1,78 ± 0,87; p = 0,044) oraz 
cukrzyca (b = –2,02 ± 0,91; p = 0,029).
Wnioski. Subiektywna ocena stanu zdrowia, wiek pacjentów, liczba hospitalizacji z powodu CAD oraz współwystępowa-
nie cukrzycy wpływają na adherence w terapii przewlekłej po zawale serca.
Słowa kluczowe: skala adherence, choroba wieńcowa
Folia Cardiologica 2017; 12, 1: 19–26
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